ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 170.67 USD | +0.87% |
|
-1.74% | -3.96% |
| Jan. 23 | AbbVie, Neomorph Form Collaboration to Develop Molecular Glue Degraders | MT |
| Jan. 23 | AbbVie Closes Nimble Therapeutics Purchase | MT |
Summary: AbbVie Inc.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: AbbVie Inc.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: AbbVie Inc.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 36.51 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings Chart: AbbVie Inc.
Source: Surperformance
ESG chart: AbbVie Inc.
Source: MSCI
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 299B | |||||
| 679B | |||||
| 360B | |||||
| 350B | |||||
| 242B | |||||
| 242B | |||||
| 211B | |||||
| 198B | |||||
| 147B | |||||
| 147B | |||||
| Average | 287.55B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG MSCI
A
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
ESG
Environment
Social
Governance
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.